Patents by Inventor Giuseppe Ciaramella

Giuseppe Ciaramella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11207398
    Abstract: Provided herein, in some embodiments, are Zika virus RNA vaccines and methods of producing an antigen-specific immune response in a subject.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: December 28, 2021
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Patent number: 11197927
    Abstract: The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: December 14, 2021
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John
  • Patent number: 11103578
    Abstract: Provided herein, in some embodiments, are vaccines (and vaccination methods) that include a ribonucleic acid (RNA) polynucleotide encoding a human metapneumovirus (hMPV) F protein and a RNA polynucleotide encoding a human parainfluenza virus 3 (hPrV3) F protein.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: August 31, 2021
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Publication number: 20210252129
    Abstract: The disclosure relates to Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 19, 2021
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Vladimir Presnyak, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
  • Publication number: 20210220467
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 22, 2021
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
  • Patent number: 11045540
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: June 29, 2021
    Assignee: ModernaTX, Inc.
    Inventor: Giuseppe Ciaramella
  • Publication number: 20210187097
    Abstract: The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.
    Type: Application
    Filed: March 15, 2018
    Publication date: June 24, 2021
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kerim Babaoglu, Jessica Anne Flynn, Lan Zhang, David Nickle
  • Publication number: 20210170016
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 10, 2021
    Applicant: ModernaTX, Inc.
    Inventor: Giuseppe Ciaramella
  • Patent number: 11007260
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: May 18, 2021
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tai Zaks, Sunny Himansu
  • Patent number: 10933127
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: March 2, 2021
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Patent number: 10925958
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: February 23, 2021
    Assignee: ModernaTX, Inc.
    Inventor: Giuseppe Ciaramella
  • Publication number: 20210046173
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 18, 2021
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Andrew J. Bett, Pedro Cejas, Lan Zhang, Christine Shaw
  • Publication number: 20200405844
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: June 10, 2020
    Publication date: December 31, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Publication number: 20200368343
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: June 10, 2020
    Publication date: November 26, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu
  • Publication number: 20200368344
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: June 10, 2020
    Publication date: November 26, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
  • Publication number: 20200369748
    Abstract: This disclosure relates to compositions and methods for treating and preventing chikungunya virus infection by delivering polynucleotides encoding anti-chikungunya virus antibodies to a subject. Compositions and treatments provided herein include one or more polynucleotides having an open reading frame encoding an anti-chikungunya virus antibody heavy chain or fragment thereof and/or an anti-chikungunya virus antibody light chain or fragment thereof. Methods for preparing and using such treatments are also provided.
    Type: Application
    Filed: January 4, 2019
    Publication date: November 26, 2020
    Inventors: Sunny Himansu, James E. Crowe, Jr., Giuseppe Ciaramella
  • Publication number: 20200338190
    Abstract: The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: May 1, 2020
    Publication date: October 29, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John
  • Publication number: 20200289639
    Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
    Type: Application
    Filed: April 21, 2020
    Publication date: September 17, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
  • Publication number: 20200289638
    Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
    Type: Application
    Filed: April 16, 2020
    Publication date: September 17, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
  • Publication number: 20200282046
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 10, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu